HRP20120554T1 - Indoli i njihova terapijska uporaba - Google Patents
Indoli i njihova terapijska uporaba Download PDFInfo
- Publication number
- HRP20120554T1 HRP20120554T1 HRP20120554AT HRP20120554T HRP20120554T1 HR P20120554 T1 HRP20120554 T1 HR P20120554T1 HR P20120554A T HRP20120554A T HR P20120554AT HR P20120554 T HRP20120554 T HR P20120554T HR P20120554 T1 HRP20120554 T1 HR P20120554T1
- Authority
- HR
- Croatia
- Prior art keywords
- fluoro
- compound according
- ylmethyl
- sulfonyl
- methyl
- Prior art date
Links
- 150000002475 indoles Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 13
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 7
- 239000001257 hydrogen Substances 0.000 claims abstract 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 6
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims abstract 6
- 125000001544 thienyl group Chemical group 0.000 claims abstract 6
- 125000002883 imidazolyl group Chemical group 0.000 claims abstract 5
- 125000001786 isothiazolyl group Chemical group 0.000 claims abstract 5
- 125000001424 substituent group Chemical group 0.000 claims abstract 5
- 125000000335 thiazolyl group Chemical group 0.000 claims abstract 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims abstract 4
- 125000002541 furyl group Chemical group 0.000 claims abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims abstract 4
- 125000002971 oxazolyl group Chemical group 0.000 claims abstract 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims abstract 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims abstract 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 239000000460 chlorine Substances 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 239000011737 fluorine Substances 0.000 claims 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 5
- -1 {5-fluoro-2-methyl-3-[3-(thiophen-2-sulfonyl)thiophen-2-ylmethyl]indol-1-yl}acetic acid {5-fluoro-2-methyl-3-[3-(pyridin-2-sulfonyl)thiophen-2-ylmethyl]indol-1-yl}acetic acid Chemical compound 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- VBFMRMAXDIETCL-UHFFFAOYSA-N 2-[3-[(5-chloro-3-pyridin-2-ylsulfonylthiophen-2-yl)methyl]-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1CC=1SC(Cl)=CC=1S(=O)(=O)C1=CC=CC=N1 VBFMRMAXDIETCL-UHFFFAOYSA-N 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000028004 allergic respiratory disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 4
- 102000009389 Prostaglandin D receptors Human genes 0.000 abstract 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Spoj koji je derivat indola formule I ili njegova farmaceutski prihvatljiva sol gdje X je SOili SO NR gdje je veza označena zvjezdicom spojena na Ar R je vodik fluor klor CN ili CF R je vodik fluor ili klor R je vodik C C alkil ili C C cikloalkil Ar je ili eročlana heteroarilna skupina izabrana između furanil tienil oksazolil tiazolil imidazolil pirazolil izoksazolil izotiazolil piridinil piridazinil pirimidinil i pirazinil gdje su fenil ili heteroarilne skupine po izboru supstituirane jednim ili višesupstituenata nezavisno izabranih između fluor klor CN C C cikloalkil O C C alkil ili C C alkil zadnje dvije skupine su po izboru supstituirane jednim ili više atoma fluora iAr je ili eročlana heteroarilna skupina izabrana između pirolil furanil tienil oksazolil tiazolil imidazolil pirazolil izoksazolil izotiazolil piridinil piridazinil pirimidinil i pirazinil gdje sufenil ili heteroarilne skupine po izboru supstituirane jednim ili više supstituenata nezavisno izabranih između fluor klor CN C C cikloalkil O C C alkil ili C C alkil zadnje dvije skupine su po izboru supstituirane jednim ili više atoma fluora Patent sadrži još patentnih zahtjeva
Claims (12)
1. Spoj koji je derivat indola formule (I), ili njegova farmaceutski prihvatljiva sol:
[image]
gdje X je -SO2- ili *-SO2NR3- gdje je veza označena zvjezdicom spojena na Ar1;
R1 je vodik, fluor, klor, CN ili CF3;
R2 je vodik, fluor ili klor;
R3 je vodik, C1-C8alkil ili C3-C7cikloalkil;
Ar1 je 5- ili 6-eročlana heteroarilna skupina izabrana između furanil, tienil, oksazolil, tiazolil, imidazolil, pirazolil, izoksazolil, izotiazolil, piridinil, piridazinil, pirimidinil i pirazinil, gdje su fenil ili heteroarilne skupine po izboru supstituirane jednim ili više supstituenata nezavisno izabranih između fluor, klor, CN, C3-C7cikloalkil, -O(C1-C4alkil) ili C1-C6alkil, zadnje dvije skupine su po izboru supstituirane jednim ili više atoma fluora; i
Ar2 je 5- ili 6-eročlana heteroarilna skupina izabrana između pirolil, furanil, tienil, oksazolil, tiazolil, imidazolil, pirazolil, izoksazolil, izotiazolil, piridinil, piridazinil, pirimidinil i pirazinil, gdje su fenil ili heteroarilne skupine po izboru supstituirane jednim ili više supstituenata nezavisno izabranih između fluor, klor, CN, C3-C7cikloalkil, -O(C1-C4alkil) ili C1-C6alkil, zadnje dvije skupine su po izboru supstituirane jednim ili više atoma fluora.;
2. Spoj prema zahtjevu 1 gdje R2 je vodik i R1 je fluor ili klor.;
3. Spoj prema zahtjevu 1 ili zahtjevu 2 gdje X je *-SO2NR3- gdje je veza označena zvjezdicom spojena na Ar1.
4. Spoj prema bilo kojem od prethodnih zahtjeva gdje je radikal Ar2SO2- ili Ar2N(R3)SO2- u meta ili para položaju prstena Ar1 u odnosu na točku veze Ar1 i ostatka molekule.
5. Spoj prema bilo kojem od zahtjeva 1 do 3 gdje je radikal Ar2SO2- ili Ar2N(R3)SO2- u orto položaju prstena Ar1 u odnosu na točku veze Ar1 i ostatka molekule.
6. Spoj prema bilo kojem od prethodnih zahtjeva gdje je Ar1 izabran između tienil, piridinil, pirimidinil, tiazolil, izotiazolil i imidazolil.
7. Spoj prema bilo kojem od prethodnih zahtjeva gdje je prsten Ar2 izabran između tienil, piridinil i pirimidinil.
8. Spoj prema bilo kojem od prethodnih zahtjeva gdje su izborni supstituenti u Ar1 i Ar2 izabrani između klor, fluor, -CN i metil.
9. Spoj prema zahtjevu 1, izabran između
{5-fluor-2-metil-3-[3-(tiofen-2-sulfonil)tiofen-2-ilmetil]indol-1-il}octena kiselina
{5-fluor-2-metil-3-[3-(piridin-2-sulfonil)tiofen-2-ilmetil]indol-1-il}octena kiselina
{5-fluor-3-[3-(piridin-3-sulfonil)tiofen-2-ilmetil]-2-metilindol-1-il}octena kiselina
{5-fluor-2-metil-3-[3-(piridin-4-sulfonil)tiofen-2-ilmetil]indol-1-il}octena kiselina
{5-klor-2-metil-3-[3-(piridin-2-sulfonil)tiofen-2-ilmetil]indol-1-il}octena kiselina
{5-fluor-2-metil-3-[5-(piridin-2-sulfonil)tiazol-4-ilmetil]indol-1-il}octena kiselina
{5-fluor-2-metil-3-[5-metil-3-(piridin-2-sulfonil)tiofen-2-ilmetil]indol-1-il}octena kiselina
{5-fluor-2-metil-3-[4-(piridin-2-sulfonil)tiazol-5-ilmetil]indol-1-il}octena kiselina
{3-[5-klor-3-(piridin-2-sulfonil)tiofen-2-ilmetil]-5-fluor-2-metilindol-1-il}octena kiselina
i njegove farmaceutski prihvatljive soli.
10. Farmaceutska smjesa koja sadrži spoj prema bilo kojem od prethodnih zahtjeva i farmaceutski prihvatljivi nosač.
11. Spoj prema bilo kojem od zahtjeva 1 do 9, za uporabu u liječenju astme, kronične opstruktivne plućne bolesti, rinitisa, sindroma alergije dišnih putova ili alergijskog rinobronhitisa.
12. Spoj prema bilo kojem od zahtjeva 1 do 9, za uporabu u liječenju psorijaze, atopijskog i ne atopijskog dermatitisa, Crohnove bolesti, ulceroznog kolitisa ili iritabilne bolesti crijeva.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0724429A GB0724429D0 (en) | 2007-12-14 | 2007-12-14 | Compounds |
| GB0806083A GB0806083D0 (en) | 2008-04-03 | 2008-04-03 | Compounds |
| GB0814910A GB0814910D0 (en) | 2008-08-14 | 2008-08-14 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120554T1 true HRP20120554T1 (hr) | 2012-07-31 |
Family
ID=40328483
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110414T HRP20110414T1 (hr) | 2007-12-14 | 2011-06-03 | Indoli i njihova uporaba u liječenju |
| HRP20120554AT HRP20120554T1 (hr) | 2007-12-14 | 2012-07-06 | Indoli i njihova terapijska uporaba |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110414T HRP20110414T1 (hr) | 2007-12-14 | 2011-06-03 | Indoli i njihova uporaba u liječenju |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8394836B2 (hr) |
| EP (2) | EP2327693B9 (hr) |
| JP (1) | JP5327762B2 (hr) |
| CN (1) | CN101970405A (hr) |
| AT (1) | ATE502920T1 (hr) |
| AU (1) | AU2008337342B2 (hr) |
| BR (1) | BRPI0820872A2 (hr) |
| CA (1) | CA2707785C (hr) |
| CY (2) | CY1111585T1 (hr) |
| DE (1) | DE602008005796D1 (hr) |
| DK (2) | DK2327693T3 (hr) |
| EA (1) | EA017573B1 (hr) |
| ES (1) | ES2386340T3 (hr) |
| HR (2) | HRP20110414T1 (hr) |
| IL (1) | IL206087A (hr) |
| MX (1) | MX2010006341A (hr) |
| NZ (1) | NZ585888A (hr) |
| PL (2) | PL2327693T3 (hr) |
| PT (2) | PT2229358E (hr) |
| SI (2) | SI2229358T1 (hr) |
| WO (1) | WO2009077728A1 (hr) |
| ZA (1) | ZA201003872B (hr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| DK2046740T3 (da) | 2006-07-22 | 2012-08-20 | Oxagen Ltd | Forbindelser med CRTH2-antagonistisk virkning |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| NZ587251A (en) * | 2008-01-18 | 2011-12-22 | Oxagen Ltd | Indole derivatives having CRTH2 antagonist activity |
| JP2011509991A (ja) | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| CN102791689B (zh) | 2010-03-22 | 2014-10-29 | 埃科特莱茵药品有限公司 | 3-（杂芳基-氨基）-1,2,3,4-四氢-9h-咔唑衍生物及其作为前列腺素d2受体调节剂的用途 |
| WO2012009134A1 (en) * | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| LT2697223T (lt) | 2011-04-14 | 2016-10-10 | Actelion Pharmaceuticals Ltd. | 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indolacto rūgšties dariniai ir jų, kaip prostaglandino d2 receptoriaus moduliatorių, panaudojimas |
| LT2781508T (lt) * | 2011-11-17 | 2019-03-12 | Kbp Biosciences Co., Ltd. | Azoto turintys kondensuoti žiediniai junginiai, skirti panaudoti kaip crth2 antagonistai |
| AU2012351342A1 (en) * | 2011-12-16 | 2014-07-24 | Atopix Therapeutics Limited | Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| EP3382391A1 (en) | 2012-10-24 | 2018-10-03 | NYU Winthrop Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| GB201322273D0 (en) * | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| PE20161177A1 (es) | 2014-03-17 | 2016-11-18 | Actelion Pharmaceuticals Ltd | Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2 |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| JPWO2015190316A1 (ja) * | 2014-06-09 | 2017-04-20 | 住友化学株式会社 | ピリジン化合物の製造方法 |
| ES2867757T3 (es) | 2015-09-15 | 2021-10-20 | Idorsia Pharmaceuticals Ltd | Formas cristalinas |
| EP3399968B8 (en) | 2016-01-07 | 2021-12-01 | Xuanzhu Biopharmaceutical Co., Ltd. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
| WO2017119732A1 (en) | 2016-01-08 | 2017-07-13 | Samsung Electronics Co., Ltd. | Electronic device and operating method thereof |
| CN108884445A (zh) | 2016-03-09 | 2018-11-23 | 北京智康博药肿瘤医学研究有限公司 | 肿瘤细胞悬浮培养物和相关方法 |
| AU2017298256B2 (en) * | 2016-07-21 | 2020-11-26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Indole derivative used as CRTH2 inhibitor |
| JP2020533595A (ja) | 2017-09-13 | 2020-11-19 | プロジェニティ， インコーポレイテッド | 子癇前症バイオマーカならびに関連するシステムおよび方法 |
| CN109096186B (zh) * | 2018-09-29 | 2020-08-04 | 中南大学 | 一种2-芳磺酰基喹啉衍生物的合成方法 |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| CN113425714B (zh) * | 2021-08-04 | 2022-04-26 | 华南师范大学 | 吲哚乙酸在制备防治慢性阻塞性肺病药物中的应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997002289A1 (en) | 1995-07-06 | 1997-01-23 | Zeneca Limited | Peptide inhibitors of fibronectine |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| JP2001163899A (ja) | 1999-12-09 | 2001-06-19 | Natl Inst Of Sericultural & Entomological Science | 機能性絹フィブロインの製造方法とその利用 |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| EP1424325A4 (en) | 2001-09-07 | 2005-12-21 | Ono Pharmaceutical Co | INDOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE AGENT |
| EP1458682B1 (en) | 2001-12-20 | 2006-08-30 | Bayer HealthCare AG | 1,4-dihydro-1,4-diphenylpyridine derivatives |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| JPWO2003097042A1 (ja) | 2002-05-16 | 2005-09-15 | 塩野義製薬株式会社 | Ｐｇｄ２受容体拮抗剤 |
| JP4484108B2 (ja) | 2002-05-16 | 2010-06-16 | 塩野義製薬株式会社 | Ｐｇｄ２受容体拮抗作用を有する化合物 |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| US7211672B2 (en) | 2002-10-04 | 2007-05-01 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| MXPA05003660A (es) | 2002-10-21 | 2005-06-08 | Warner Lambert Co | Derivados de quinolina como antagonistas de crth2. |
| EP1413306A1 (en) | 2002-10-21 | 2004-04-28 | Warner-Lambert Company LLC | Tetrahydroquinoline derivatives as CRTH2 antagonists |
| NZ541234A (en) | 2002-12-20 | 2008-06-30 | Amgen Inc | Asthma and allergic inflammation modulators |
| EP1435356A1 (en) | 2003-01-06 | 2004-07-07 | Warner-Lambert Company LLC | Quinoline derivatives as CRTH2 antagonists |
| WO2004078719A1 (ja) | 2003-03-06 | 2004-09-16 | Ono Pharmaceutical Co., Ltd. | インドール誘導体化合物およびその化合物を有効成分とする薬剤 |
| SE0301009D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| WO2005007094A2 (en) | 2003-07-09 | 2005-01-27 | Tularik Inc. | Asthma and allergic inflammation modulators |
| SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| EP1675826A1 (en) | 2003-10-14 | 2006-07-05 | Oxagen Limited | Compounds having crth2 antagonist activity |
| WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
| GB2407318A (en) | 2003-10-23 | 2005-04-27 | Oxagen Ltd | Substituted Indol-3-yl acetic acid derivatives |
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| DE602005021770D1 (de) | 2004-03-11 | 2010-07-22 | Actelion Pharmaceuticals Ltd | Indol-1-yl-essigsäurederivate |
| RU2006138603A (ru) | 2004-04-07 | 2008-05-20 | Милленниум Фармасьютикалз, Инк. (Us) | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний |
| CN100537153C (zh) | 2004-04-20 | 2009-09-09 | 阿科布兰兹美国有限责任公司 | 订书机 |
| GB0409921D0 (en) | 2004-05-04 | 2004-06-09 | Novartis Ag | Organic compounds |
| JP2008500991A (ja) | 2004-05-29 | 2008-01-17 | ７ティーエム ファーマ エイ／エス | 医学的使用のためのｃｒｔｈ２レセプターリガンド |
| KR20070089908A (ko) | 2004-09-21 | 2007-09-04 | 아더시스 인코포레이티드 | Ｃｒｔｈ２ 수용체 길항작용을 나타내는 인돌 아세트산 및이의 용도 |
| ATE517085T1 (de) | 2004-11-23 | 2011-08-15 | Astrazeneca Ab | Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate |
| GB0427381D0 (en) | 2004-12-14 | 2005-01-19 | Novartis Ag | Organic compounds |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| AU2006216713A1 (en) | 2005-02-24 | 2006-08-31 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| GB0505048D0 (en) * | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| GB0510584D0 (en) | 2005-05-24 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0510585D0 (en) | 2005-05-24 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0512944D0 (en) | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Indolizine compounds |
| GB0518783D0 (en) | 2005-09-14 | 2005-10-26 | Argenta Discovery Ltd | Indolizine compounds |
| BRPI0616452B8 (pt) | 2005-09-30 | 2021-05-25 | Argenta Discovery Ltd | quinolinas e seu uso terapêutico |
| GB0521275D0 (en) | 2005-10-19 | 2005-11-30 | Argenta Discovery Ltd | 3-Aminoindole compounds |
| WO2007062678A1 (en) | 2005-11-29 | 2007-06-07 | 7Tm Pharma A/S | Phenoxyacetic acid derivatives as crth2 receptor ligands |
| GB0524428D0 (en) | 2005-11-30 | 2006-01-11 | 7Tm Pharma As | Medicinal use of receptor ligands |
| GB0525141D0 (en) | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| CN102558021A (zh) | 2006-05-26 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | 联芳基或芳基-杂芳基取代的吲哚类化合物 |
| GB0611695D0 (en) | 2006-06-13 | 2006-07-26 | Novartis Ag | Organic compounds |
| DK2046740T3 (da) * | 2006-07-22 | 2012-08-20 | Oxagen Ltd | Forbindelser med CRTH2-antagonistisk virkning |
| AU2006352195A1 (en) | 2006-12-21 | 2008-06-26 | Argenta Discovery Limited | CRTH2 antagonists |
| WO2008113965A1 (en) | 2007-03-21 | 2008-09-25 | Argenta Discovery Limited | Indolizine acetic acid derivatives as crth2 antagonists |
| CN101715441A (zh) | 2007-03-29 | 2010-05-26 | 阿根塔口腔治疗有限公司 | 作为crth2受体配体的喹啉衍生物 |
| US8173812B2 (en) | 2007-04-04 | 2012-05-08 | Pulmagen Therapeutics (Asthma) Limited | Quinolines and their therapeutic use |
| GB0722203D0 (en) * | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
-
2008
- 2008-12-12 DE DE602008005796T patent/DE602008005796D1/de active Active
- 2008-12-12 PT PT08862784T patent/PT2229358E/pt unknown
- 2008-12-12 PL PL10193389T patent/PL2327693T3/pl unknown
- 2008-12-12 WO PCT/GB2008/004107 patent/WO2009077728A1/en active Application Filing
- 2008-12-12 EP EP10193389A patent/EP2327693B9/en not_active Not-in-force
- 2008-12-12 US US12/746,104 patent/US8394836B2/en not_active Expired - Fee Related
- 2008-12-12 PT PT10193389T patent/PT2327693E/pt unknown
- 2008-12-12 AU AU2008337342A patent/AU2008337342B2/en not_active Ceased
- 2008-12-12 CA CA2707785A patent/CA2707785C/en not_active Expired - Fee Related
- 2008-12-12 CN CN2008801267027A patent/CN101970405A/zh active Pending
- 2008-12-12 MX MX2010006341A patent/MX2010006341A/es active IP Right Grant
- 2008-12-12 DK DK10193389.3T patent/DK2327693T3/da active
- 2008-12-12 EP EP08862784A patent/EP2229358B1/en not_active Not-in-force
- 2008-12-12 NZ NZ585888A patent/NZ585888A/en not_active IP Right Cessation
- 2008-12-12 AT AT08862784T patent/ATE502920T1/de active
- 2008-12-12 SI SI200830260T patent/SI2229358T1/sl unknown
- 2008-12-12 PL PL08862784T patent/PL2229358T3/pl unknown
- 2008-12-12 JP JP2010537514A patent/JP5327762B2/ja not_active Expired - Fee Related
- 2008-12-12 BR BRPI0820872-7A patent/BRPI0820872A2/pt not_active Application Discontinuation
- 2008-12-12 DK DK08862784.9T patent/DK2229358T3/da active
- 2008-12-12 SI SI200830693T patent/SI2327693T1/sl unknown
- 2008-12-12 ES ES10193389T patent/ES2386340T3/es active Active
- 2008-12-12 EA EA201070731A patent/EA017573B1/ru not_active IP Right Cessation
-
2010
- 2010-05-31 ZA ZA2010/03872A patent/ZA201003872B/en unknown
- 2010-05-31 IL IL206087A patent/IL206087A/en active IP Right Grant
-
2011
- 2011-06-03 HR HR20110414T patent/HRP20110414T1/hr unknown
- 2011-06-23 CY CY20111100597T patent/CY1111585T1/el unknown
-
2012
- 2012-07-04 CY CY20121100592T patent/CY1113179T1/el unknown
- 2012-07-06 HR HRP20120554AT patent/HRP20120554T1/hr unknown
-
2013
- 2013-01-31 US US13/755,727 patent/US20130225617A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120554T1 (hr) | Indoli i njihova terapijska uporaba | |
| PE20141372A1 (es) | Nuevos derivados dihidroquinolina-2-ona | |
| JP2009536918A5 (hr) | ||
| HRP20140705T1 (hr) | Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina | |
| JP2013544840A5 (hr) | ||
| HRP20160292T1 (hr) | Derivati 1-fenil-2-piridinilalkil-alkohola kao inhibitori fosfodiesteraze | |
| ES2615742T3 (es) | Benzamidas sustituidas con actividad hacia receptores EP4 | |
| HRP20150588T1 (hr) | Parazitocidni spojevi dihidroizoksazola | |
| JP2013505969A5 (hr) | ||
| HRP20141209T2 (hr) | Modulatori receptora prostaciklina (pgi2) korisni za liječenje poremećaja povezanih s time | |
| RU2013125480A (ru) | Стимуляторы sgc | |
| HRP20141208T1 (hr) | Derivati 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-karbazola i njihova uporaba kao modulatora receptora prostaglandina d2 | |
| PE20081889A1 (es) | Indol carboxamidas como inhibidores de ikk2 | |
| MX2009008509A (es) | Compuesto de anillo puenteado-aza. | |
| PE20110928A1 (es) | Derivados de 4-azetidinil-1-heteroaril-ciclohexanol como antagonistas de ccr2 | |
| HRP20201494T1 (hr) | Spojevi heteroaril-karboksamida kao inhibitori ripk2 | |
| RU2015145989A (ru) | Замещенное биарильное соединение | |
| HRP20192121T1 (hr) | Derivati pirido-oksazinona kao tnap inhibitori | |
| HRP20161235T1 (hr) | Derivati 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido(1,2-a)indol-octene kiseline i njihova uporaba kao modulatori receptora prostaglandina d2 | |
| HRP20191779T1 (hr) | Tiazolski modulatori adenozinskih receptora a3 | |
| HRP20090647T1 (hr) | Novi derivati 3-fenilpropionske kiseline i nihova uporaba kao ppar-gama receptorskih liganada | |
| MEP10109A (en) | Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof | |
| JP2013538786A5 (hr) | ||
| RS52262B (en) | NEW DERIVATIVES (PIPERANISIL PONTE) -1-ALKANONE AND THEIR USE AS AN INHIBITOR p75 | |
| JP2007507465A5 (hr) |